Recent News

• 05.13.2025 - Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development
• 05.07.2025 - Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025
• 04.24.2025 - Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast
• 04.24.2025 - From Philly to Rio: International Collaboration on CAR T-Cell Manufacturing & Delivery Brings Costs Down
• 03.25.2025 - How Can Your LIMS Enhance Clinical Research?
• 03.24.2025 - Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report
• 03.10.2025 - Azenta to Participate in the Virtual KeyBanc Capital Markets Healthcare Forum
• 02.13.2025 - Choosing the Right Tubes for Sample Integrity

Recent Filings

• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.09.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2025 - EX-99.1 EX-99.1
• 05.07.2025 - 8-K Current report
• 04.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.09.2025 - 8-K Current report
• 02.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2025 - 4 Statement of changes in beneficial ownership of securities